Imipramine + Pregabalin + Imipramine, pregabalin + Placebo
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polyneuropathy
Conditions
Polyneuropathy
Trial Timeline
Feb 1, 2010 → Mar 1, 2013
NCT ID
NCT01047488About Imipramine + Pregabalin + Imipramine, pregabalin + Placebo
Imipramine + Pregabalin + Imipramine, pregabalin + Placebo is a approved stage product being developed by Pfizer for Polyneuropathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT01047488. Target conditions include Polyneuropathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01047488 | Approved | UNKNOWN |
Competing Products
20 competing products in Polyneuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Qutenza + Pregabalin | Astellas Pharma | Approved | 85 |
| Ranirestat + Placebo | Eisai | Phase 2/3 | 65 |
| KITE-363 + Fludarabine + Cyclophosphamide | Gilead Sciences | Phase 1 | 32 |
| Fx-1006A + Placebo | Pfizer | Phase 2/3 | 64 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Fx-1006A | Pfizer | Phase 2/3 | 64 |
| Riliprubart Prefilled Pen (PFP) | Sanofi | Phase 3 | 76 |
| riliprubart + Placebo + riliprubart + Placebo + IVIg + Placebo | Sanofi | Phase 3 | 76 |
| Intravenous Immunoglobulin | CSL | Pre-clinical | 22 |
| IgPro10 | CSL | Approved | 84 |
| Immune Globulin Subcutaneous (Human) | CSL | Pre-clinical | 22 |
| IgPro20 | CSL | Phase 3 | 76 |
| Hizentra | CSL | Pre-clinical | 22 |
| 10% liquid formulation of human immunoglobulin | CSL | Phase 3 | 76 |
| IgPro20 (low dose) + Placebo + IgPro10 + IgPro20 (high dose) | CSL | Phase 3 | 76 |
| levetiracetam | UCB | Phase 2 | 49 |
| Rozanolixizumab | UCB | Pre-clinical | 20 |